Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

To evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of the humanised antiepidermal growth factor receptor monoclonal antibody matuzumab combined with epirubicin, cisplatin and capecitabine (ECX) in patients as first-line treatment for advanced oesophagogastric cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, S, Starling, N, Cunningham, D, Benson, M, Wotherspoon, A, Lüpfert, C, Kurek, R, Oates, J, Baselga, J, Hill, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538760/
https://www.ncbi.nlm.nih.gov/pubmed/19238629
http://dx.doi.org/10.1038/sj.bjc.6604622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538760/
https://www.ncbi.nlm.nih.gov/pubmed/19238629
http://dx.doi.org/10.1038/sj.bjc.6604622

Ejemplares similares